Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction

Current Hypertension Reports
Sean P Collins, Jennifer L Martindale

Abstract

In spite of advances in our understanding of acute heart failure (AHF) and its different phenotypic expressions, AHF management is still centered on volume removal with intravenous diuretics. This narrative review describes the pathophysiology underlying hypertensive AHF and appraises therapies targeting these mechanisms. Vascular redistribution rather than volume overload may be the primary determinant of elevated cardiac filling pressures and subsequent pulmonary congestion in patients with hypertensive AHF; in these patients, vasodilators should be the predominant treatment. Additional therapy with diuretics in hypertensive AHF should be relegated to the treatment of overt volume overload or persistent congestion in spite of optimized hemodynamics. Intravenous nitroglycerin at high doses can rapidly achieve pulmonary decongestion and reduce downstream critical care needs in these patients. The therapeutic role for synthetic peptides with vasodilator properties has yet to be defined. Evidence supporting both old and new vasodilator therapies is limited by a paucity of well-designed studies and failure to demonstrate improvement in long-term outcomes. Targeted study of this phenotype of AHF is needed before vasodilator therapi...Continue Reading

References

Mar 21, 2003·Reproductive Biology and Endocrinology : RB&E·Silvia Nistri, Daniele Bani
Jan 24, 2004·Anesthesiology·Simon Gelman, Phillip S Mushlin
Mar 6, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Matthias SchmittMichael P Frenneaux
Nov 9, 2006·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN OPTIMIZE-HF Investigators and Coordinators
Aug 21, 2007·Journal of the American College of Cardiology·Gregg C FonarowUNKNOWN OPTIMIZE-HF Investigators and Hospitals
Apr 29, 2010·Current Heart Failure Reports·Sam L TeichmanMarco Metra
Jul 8, 2011·The New England Journal of Medicine·C M O'ConnorR M Califf
Nov 13, 2012·Lancet·John R TeerlinkUNKNOWN RELAXin in Acute Heart Failure (RELAX-AHF) Investigators
Jun 12, 2013·Journal of the American College of Cardiology·Clyde W YancyUNKNOWN American Heart Association Task Force on Practice Guidelines
Aug 8, 2013·The Cochrane Database of Systematic Reviews·Abel WakaiCaroline Pospisil
Feb 24, 2015·The American Journal of Cardiology·David H MacIver, Andrew L Clark
Jul 1, 2015·Heart·David M ViauPhillip D Levy
Nov 9, 2016·The American Journal of Emergency Medicine·Suprat Saely WilsonPhillip D Levy
Dec 30, 2016·International Journal of Emergency Medicine·Syed Imran AyazPhillip D Levy
Apr 14, 2017·The New England Journal of Medicine·Milton PackerUNKNOWN TRUE-AHF Investigators
Aug 2, 2017·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·Jennifer L MartindaleRichard Sinert

❮ Previous
Next ❯

Citations

Jan 8, 2020·Clinical Hypertension·Gyu Chul Oh, Hyun-Jai Cho
Feb 22, 2021·Current Hypertension Reports·Nicholas HarrisonPhillip Levy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.